查加斯病诊断的回顾,进展和挑战:一个全面的审查
Alejandro Gabriel Schijman1, Julio Alonso-Padilla2,3, Constança Britto4
1Laboratorio de Biología Molecular de la Enfermedad de Chagas, Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr Héctor Torres", INGEBI- CONICET, Vuelta de Obligado 2490, Buenos Aires, 1428 ADN, Argentina.
Lancet regional health. Americas
|July 15, 2024
概括
查加斯病的及时诊断对于获得治疗和消除目标至关重要. 需要创新的点照顾测试来克服当前多测试算法的局限性,特别是在资源有限的环境中.
科学领域:
- 被忽视的热带疾病被忽视的热带疾病
- 传染病诊断 传染病诊断 传染病诊断
- 公共卫生 公共卫生
背景情况:
- 查加斯病是由Trypanosoma cruzi引起的,在全球范围内影响着数百万人.
- 世界卫生组织 (WHO) 的目标是到2030年消除它,强调诊断需求.
- 当前的诊断算法耗时,在资源有限的领域提出了挑战.
研究的目的:
- 审查历史背景和查加斯病诊断的最新进展.
- 确定改善诊断可访问性的挑战和未来方向.
- 强调需要创新的工具来实现消除目标.
主要方法:
- 对寄生虫学,分子学和血清学诊断方法的审查.
- 对诊断性能,灵敏度和特异性的分析.
- 探索医疗保健点检测策略的探索.
主要成果:
- 寄生虫学方法缺乏灵敏度;分子方法提供量化和吞吐量.
- 血清学工具面临的挑战是寄生虫抗原的多样性.
- 护理点测试对于可访问性和疾病控制至关重要.
结论:
- 尽管取得了进展,但查加斯病诊断方面的挑战仍然存在.
- 创新的诊断策略,特别是护理点测试,对于广泛的可访问性至关重要.
- 在控制查加斯病方面取得全面进展的关键是平衡成就和障碍.
相关概念视频
Toxoplasmosis
Toxoplasmosis, a zoonotic disease caused by the protozoan Toxoplasma gondii, poses significant public health challenges globally due to its high seroprevalence and varied clinical manifestations. As an obligate intracellular parasite, T. gondii can infect all warm-blooded vertebrates, but felids are its only definitive hosts, shedding unsporulated oocysts into the environment. Humans typically acquire the infection through ingestion of tissue cysts in undercooked meat or oocysts from...
American Trypanosomiasis
Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...


